Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)

Next Previous
X
Search
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LX 9211 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RELIEF-PHN1
  • Sponsors Lexicon Pharmaceuticals

    • Most Recent Events

    • 27 Apr 2023 Results for safety and efficacy, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 21 Apr 2023 According to a Lexicon Pharmaceuticals media release, study investigators will present trial data at The British Pain Society 56th Annual Scientific Meeting.
    • 21 Apr 2023 According to a Lexicon Pharmaceuticals media release, results from the study will be presented during the Emerging Science session at the American Academy Of Neurology (AAN) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top